Nature Reviews Clinical Oncology

Aims & Scope

Nature Reviews' clinical content is written by internationally renowned clinical academics and researchers and targeted towards readers in the medical sciences, from postgraduate level upwards.

While intended to be read by practicing doctors, researchers and academics within a specialty, we aim to make all our articles accessible to readers working in any medical discipline.

In-depth Reviews present authoritative, up-to-date information on a topic, placing it in the context of a field's history and development.

Topical discussion and opinions are proffered in Perspectives and News & Views articles, and in the Research Highlights section we filter primary research from a range of specialty and general medical journals.

View Aims & Scope

---

Metrics & Ranking

Impact Factor

Year	Value
2025	82.2
2024	81.10

SJR (SCImago Journal Rank)

Year	Value
2024	28.675

Quartile

Year	Value
2024	Q1

h-index

Year	Value
2024	238

Journal Rank

Year	Value
2024	6

Journal Citation Indicator

Year	Value
2024	13125

---

---

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Web of Science
• Medline
• Embase

---

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Medicine, designed to support cutting-edge academic discovery.

---

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Radiomics: the bridge between medical imaging and personalized medicine

  Citation: 4292

  Authors: Philippe, Ralph T.H., Timo M., Jurgen, Evelyn E.C., Janita, Sebastian, Ruben T.H.M., Aniek J.G., Arthur, Yvonka, Henry, Johan, Tim, Erik, Wouter, Andre, Felix M., Joachim E., Sean

• Tumour-associated macrophages as treatment targets in oncology

  Citation: 3228

  Authors: Alberto, Federica, Alberto, Luigi, Paola

• Tumour heterogeneity and resistance to cancer therapies

  Citation: 2922

  Authors: Ibiayi, Alice T.

• Clinical development and potential of photothermal and photodynamic therapies for cancer

  Citation: 2877

  Authors: Xingshu, Jonathan F., Juyoung, Xiaoyuan

• Delivering nanomedicine to solid tumors

  Citation: 2710

  Authors: Rakesh K., Triantafyllos

• Targeting the IL-6/JAK/STAT3 signalling axis in cancer

  Citation: 2364

  Authors: Daniel E., Rachel A., Jennifer R.

• Broadening horizons: the role of ferroptosis in cancer

  Citation: 2207

  Authors: Xin, Rui, Guido, Daolin

• Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease

  Citation: 2206

  Authors: Giampaolo, Justin M., Ingrid A., Melinda E., Luca

• EMT, CSCs, and drug resistance: the mechanistic link and clinical implications

  Citation: 2070

  Authors: Tsukasa, Robert A.

• Targeting apoptosis in cancer therapy

  Citation: 1970

  Authors: Benedito A., Wafik S.

---